Profile

Business Description

Relmada Therapeutics is a clinical-stage, publicly traded biotechnology company developing REL-1017 (dextromethadone) in multiple indications. RELM-1017 is in Phase 2 for treatment resistant depression and preclinical testing for additional indications. The Company's product development efforts are guided by the internationally recognized scientific expertise of its research team. The Company's approach is expected to reduce clinical development risks and costs while potentially delivering valuable products to address areas of high unmet medical needs.

Company Info

Address:
750 Third Avenue
9th Floor
New York, NY 10017 US

Telephone:
212-547-9591

Email:
info@relmada.com

Industry Classifications

Sector:
Healthcare

Industry:
Drug Manufacturers

NAICS:
Pharmaceutical Preparation Manufacturing (325412)

SIC:
Pharmaceutical Preparations (2834)